GlassScriptPhysician profile
Sami Abdulmassih
NPI 1760777270
$2,067.61
in general payments reported to CMS, 2019-2025
21 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.51 · 2020: $69.89 · 2021: $152 · 2022: $168 · 2023: $172 · 2024: $235 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $440.41 | 2024-2025 | Repatha, Evenity, Repatha |
| Lilly USA, LLC | $280.19 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $172.29 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $165.23 | 2019-2021 | |
| Medtronic, INC. | $157.39 | 2022-2024 | Minimed 780g |
| Abbott Laboratories | $149.35 | 2021-2025 | Freestyle Libre 3 |
| Ethicon US, LLC | $143.89 | 2025 | Linx Reflux Management System |
| Astrazeneca Pharmaceuticals LP | $119.25 | 2024-2025 | Farxiga |
| Abbvie INC. | $81.87 | 2025 | |
| Exact Sciences Corporation | $78.27 | 2024-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $72.91 | 2021-2022 | |
| Boston Scientific Corporation | $39.98 | 2025 | Enroute Transcarotid Neuroprotection System |
| Dynavax Technologies Corporation | $28.96 | 2024-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $28.46 | 2023-2025 | |
| Biotronik Nro, INC. | $20.40 | 2024 | Prospera |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.63 | 2024 | Xarelto |
| Pfizer INC. | $15.28 | 2025 | |
| Daiichi Sankyo INC. | $15.00 | 2021 | |
| Astellas Pharma US INC | $14.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2025 | Austedo Xr |
| Arbor Pharmaceuticals, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Abdulmassih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.